{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.87","upperLimit":"2.78","value":"2.26"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Duration of response (Aim 1.2.5) will be defined as the time from first occurrence of PR or CR until the first occurrence of PD, death, or going off study. Patients who progress will be considered to have had an event, patients who die prior to progressing will be considered to have a competing event, and patients who go off study prior to progressing will be censored at time of last contact. The analysis will be done using the method of Gray.","dispersionType":"Full Range","groups":[{"description":"Patients receive trametinib PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a bone marrow aspiration or biopsy at baseline, on day 28 of cycles 1 and 2, at all subsequent odd numbered cycles, and at end of treatment.","id":"OG000","title":"Treatment (Trametinib)"}],"paramType":"MEDIAN","populationDescription":"All patients who achieved an overall best response of Partial Response or Complete Response.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"years"}